HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology

HCG clinicians contributing to one of the largest bodies of oncology research from India

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26

Wanbury reports explosive Q3 profit surge, signals strong growth ahead

Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year

KIMS Hospitals crosses Rs. 1,000 crore quarterly revenue milestone

MHRA warns of extremely rare vision risk linked to semaglutide

Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction

£1bn London Cancer Hub expansion wins planning approval

The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site

Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY

On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY

Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure

Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come

Zydus receives FDA’s tentative approval for Dapagliflozin Tablets

Lupin launches Topiramate ER capsules in US

Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals